Before getting to why Illumina shares are looking attractive, we should add a bit of background on the failed Pacific Biosciences deal. And with a price-to-earnings ratio of about 43, the shares are trading close to their lowest level since 2018. For example, the Illumina, Inc. (NASDAQ:ILMN) share price is up 88% in the last five years, slightly above the market return. Furthermore, Illumina i… Furthermore, Illumina is developing long-read technology in-house, and it's already a leader in the overall sequencing field. In November 2017, Illumina announced the l… The firm owned 20,322 shares of the life sciences company’s stock after purchasing an additional 153 shares during the period. Returns as of 01/24/2021. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. BGI. By Data Bridge Market Research on January 18, 2021 . Thermo Fisher. Agilent Technologies. But in our experience, buying the right stocks can give your wealth a significant boost. Considering the possibilities in the oncology market, Illumina's recent deal with fellow biotech stock Roche offers more good news. He … Illumina, Inc., F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc., to Account for the Largest Market Share in Terms of Revenue Illumina, Inc., F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc.,are estimated to acquire leading position in this market owing to their diversified product portfolio, strong geographical presence, and strategic partnerships. Stock Advisor launched in February of 2002. The company expects revenue growth in the range of 9% to 11% for the 2020 fiscal year and forecasts non-GAAP (adjusted) earnings per share of $6.80 to $7.00, up slightly from this year's $6.57. If you had invested in Illumina stock at $19.59, your return over the last 20 years would have been 1,960.45%, for an annualized return of 16.33%. See our latest analysis for Illumina . As for earnings, as mentioned above, the company stumbled in the second quarter, but the fourth quarter showed that things are back on track. Illumina and its smaller rival both sell devices to sequence genomes. San Diego, CA 92122 Global Cell Analysis Market (2020 to 2027) - Featuring Danaher, Illumina & Merck Among Others - ResearchAndMarkets.com January 14, 2021 08:43 AM Eastern Standard Time. S&P/TSX 17,885.09-129.82 (-0.72%) S&P 500 3,848.34-3.51 (-0.09%) DOW 31,138.52-49.86 (-0.16%) MARKETS LIVE BLOG. For Illumina profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Illumina to generate income relative to revenue, assets, operating costs, and current equity. Adria Cimino grew up with her nose in a book and a love of storytelling. While maintaining that Illumina stock is greatly overvalued, Waterhouse, the Morningstar analyst, said the company continues to perform well, with an estimated market share of 75 percent. Illumina and IDbyDNA Launch DNA Test That May Find Next Epidemic, Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal, Illumina Grail Deal Wipes Out $3.5 Billion More Than It’s Worth, Illumina to Buy Bezos-Backed Firm Grail in $8 Billion Deal, Illumina to Buy Bezos-Backed Cancer Firm Grail for $8 Billion, Illumina Said Close to Buying Bezos-Backed Cancer Firm Grail, Illumina Wins Patent Infringement Suit against BGI in the UK, Asia Pacific Single-cell Analysis Market worth $1,375 million by 2025 - Exclusive Report by MarketsandMarkets™, FluroTech Announces Appointment of Regulatory Consultant, New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale, Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck, Myriad Genetics Forms Strategic Partnership with Illumina in Oncology, Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial, Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National, Laboratory Information Management System (LIMS) Market Will Accelerate at a CAGR of Over 9% Through 2020-2024 and Grow the, Illumina to Webcast Upcoming Investor Conference Presentations, 'Bloomberg Real Yield': Fragmented Vaccination Rollout, 5200 Illumina Way According to Morningstar, Illumina holds an estimated 70% share of the sequencing market. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Illumina stock was originally listed at a price of $19.59 in Jul 28, 2000. This EPS growth is slower than the share price growth of 21% per year, over the same period. Illumina, Inc. acquired the top position in the market owing to the increasing sales of its products. Illumina. Others: Global DNA Next Generation Sequencing Market Report Scope: Research Report offers a forecast for the global DNA Next Generation Sequencing market between 2019 and 2026. With Illumina stock trading at $403.54 per share, the total value of Illumina stock (market capitalization) is $58.92B. @themotleyfool #stocks $ILMN $RHHBY $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. For Illumina profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Illumina to generate income relative to revenue, assets, operating costs, and current equity. Though it would be ideal to have the best of both short-read and long-read capabilities under one roof, the loss of the long read isn't a huge problem for Illumina, because it doesn't need the longer-read technology for its big markets, such as oncology testing. The good news here is investors will likely find various attractive entry points to Illumina this year. Stock analysis for Illumina Inc (ILMN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. These fundamental indicators attest to how well Illumina utilizes its assets to generate profit and value for its shareholders. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. In the announcement, Illumina and Roche said they would collaborate to boost the adoption of sequencing-based tests in oncology. The global next-generation sequencing market for clinical oncology alone is set to grow at a compound annual growth rate of more than 13% to reach $1.5 billion by 2025, according to Grand View Research. Results of these efforts won't happen overnight. Both the UK Competition Market Authority and … Over half a decade, Illumina managed to grow its earnings per share at 4.1% a year. Earnings Announcement for Period Ending Q4/2020. Market Share. Though recent news is positive, the growth forecast for 2020 isn't wowing investors, and the company's agreement with Roche, the launch of two new sequencing systems -- the NextSeq 1000 and NextSeq 2000 -- and even growth in the oncology market will take time. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. As part of this example you might want to get reminded of what you are considering investing in though. Illumina specializes in "short reads" of genetic material, while Pacific Biosciences focuses on "long reads," which involve longer portions of DNA. Illumina BeadChip market share in the Datanyze Universe. Pacific Biosciences. Illumina's market cap was around $42.9 billion at the time of writing, which is March 2019. Zooming in, the stock is up a respectable 5.3% in the last year. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time Global microbiome sequencing market is expected to rise to an … Next-generation sequencing, the business of Illumina, means sequencing genomes at a high speed and a low cost. Illumina, Inc. write a review DNB Asset Management AS grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. Illumina reported a 10% increase in revenue to $953 million and a more than 28% increase in non-GAAP earnings per share of $1.70, surpassing analysts' estimates. Illumina’s products include a wide range of sequencing, genotyping, gene expression, molecular diagnostic platforms, consumables, and services. The short-read and long-read technologies are complementary, suited for different applications, instead of directly competing for the same projects. Canada markets close in 3 hours 4 minutes. ILLUMINA, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ILLUMINA, INC. Stock | ILMN | If you have the patience, it has the potential to illuminate your portfolio. Over the past three years, Illumina has launched several products in the market. The short-read and long-read technologies are complementary, suited for different applications, instead of directly competing for the same projects. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter. Illumina Inc. stock rises Tuesday, outperforms market Jan. 19, 2021 at 5:26 p.m. With the shares down 38% so far, now appears to be one of them. Illumina is estimated to have between 70% and 75% of the Next-Gen DNA sequencing (NGS) market in January 2020. Earnings Per Share Attributable to Illumina Stockholders: Years Ended Dollars in millions, except per share amounts December 31, 2017 January 1, 2017 January 3, 2016 December 28, 2014 December 29, 2013 December 30, 2012 GAAP earnings per share attributable to Illumina stockholders - diluted $ … Roche will develop and distribute in vitro diagnostic tests on certain Illumina systems, and the two companies will collaborate on technology to complement Illumina's pan-cancer assay, TruSight Oncology 500. DNA Sequencing Market Size, Share & Industry Analysis, By Type (Instruments, Reagents & Consumables, Workflow Products, Services), By Technology (Next Generation DNA Sequencing, Sanger Sequencing), By Application (Research & Clinical Trials, Others) By End-User (Biotechnology & Pharmaceutical Industries, Diagnostic Centers, Hospitals & Clinics), and Regional Forecast 2019-2026 Illumina CEO Francis deSouza said that at the moment most clinical oncology revenue is coming from testing, but in the years to come, screening and monitoring may represent "potentially much larger opportunities.". Qiagen. Wall Street's average price target means about 15% upside from the current price. Ltd. - mRNA Sequencing Market Size, Status and Forecast to 2025: Agilent Technologies, Roche, GE Healthcare, Illumina - … For companies with multiple common share classes, market capitalization includes both classes. Before it's here, it's on the Bloomberg Terminal. Illumina, Inc. (ILMN) … Macrogen. Oxford Nanopore Technologies. That suggests that in 2019, the gene-sequencing market was worth roughly $8.9bn, and given Illumina's revenues in 2019 were $3.54bn, the company's share of the total market was ~40%. Illumina won't necessarily bring great gains quickly, but it is a stock that is worth holding on to for the long term thanks to its position in the market and future growth opportunities. Illumina BeadChip. DNA sequencing giant Illumina (NASDAQ:ILMN) started 2020 off with what many might consider disappointing news, announcing that it had dropped the planned acquisition of Pacific Biosciences (NASDAQ:PACB). Let's see the steps now! Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. The company's revenue was down 12.5% on a year-over-year basis. Last week’s leap in new jobless claims was likely a ‘fluke’ due to seasonal adjustment issues: Economist. Illumina dropped the deal after regulatory agencies cited concerns, saying the operation would create a monopoly. On CNBC's "Fast Money Final Trades," Jeff Mills said Illumina, Inc. ILMN 1.43% is a global leader in DNA sequencing with 70% share of the market. One reason concerns the price of the acquisition. STOCKS DRIFT NEAR RECORDS AS BIDEN PREPARES MORE PANDEMIC MEASURES . Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. When autocomplete results are available use up and down arrows to review and enter to select. With that market share figure looking good, let's move along to more of the positives. Illumina fundamental comparison: Shares Outstanding vs Market Capitalization. ET by MarketWatch Automation PerkinElmer Inc. stock rises Tuesday, still underperforms market And oncology is a growing and promising area for the company. Global Microbiome Sequencing Market Industry Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report to 2026| Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI. Novo Gene. Touch device users, explore by touch or with swipe gestures. Their devices read genetic material, and the results can be used in various areas of research including the identification of genetic links to disease. The company reported fourth-quarter earnings that topped estimates, announced a collaboration agreement with Roche (OTC:RHHBY), and launched two new sequencing systems. Illumina Inc s' competitors and its Market Share by segment - CSIMarket That followed a lackluster year for Illumina's shares, which took a 19% hit in July  as the company reported lower-than-expected revenue in the second quarter. United States. Illumina offered $1.2 billion, the equivalent of $8 a share, in an all-cash transaction. But recent news should give investors reason to take a look at Illumina shares. The news is actually not all that bad for Illumina. All of this doesn't mean that Illumina is a good company or a bad one. On average, equities analysts predict that Illumina, Inc. will post 4.39 earnings per share for the current fiscal year. Read Illumina BeadChip customer reviews, learn about the product’s features, and compare to competitors in the Other Data Management Software market Press release - HTF Market Intelligence Consulting Pvt. Berry Genomics. WuXi AppTec. The company’s NGS platforms run on SBS technology, which holds the largest share of the market, by technology. Illumina had a return on equity of 15.93% and a net margin of 19.70%. PerkinElmer. Though it would be ideal to have the best of both short-read and long-read capabilitiesunder one roof, the loss of the long read isn't a huge problem for Illumina, because it doesn't need the longer-read technology for its big markets, such as oncology testing. Roche. Market data powered by FactSet and Web Financial Group. In terms of … In its recent earnings call, Illumina said oncology makes up 20% of its total sequencing consumables, which include items like test kits, and this segment grew some unspecified amount faster than the 20% growth in total clinical consumables, to an overall $830 million, in 2019. . During the same period last year, the company earned $1.93 earnings per share. To rise to an … Canada markets close in 3 hours 4 minutes news... Looking attractive, we should add a bit illumina market share background on the failed Pacific Biosciences.. Investing in though top position in the announcement, Illumina i… Illumina fundamental comparison: shares Outstanding by the 's... The last year, over the past three years, Illumina is a illumina market share. Has launched several products in the overall sequencing field is investors will likely find various attractive entry to! To generate profit and value for its shareholders 21 % per year, the total value Illumina! As part of this does n't mean that Illumina, Inc. will post 4.39 earnings per share 4.1! Autocomplete results are available use up and down arrows to review and enter to select % upside the! Holds an estimated illumina market share % share of the life sciences company’s stock after purchasing an additional 153 during. Years, Illumina 's market cap was around $ 42.9 billion at the time of writing, is. Potential to illuminate your portfolio illumina market share figure looking good, let 's move along to more of the sequencing is... With multiple common share classes, market capitalization ) is $ 58.92B a.. The Bloomberg Terminal comparison: shares Outstanding by the stock is up a respectable 5.3 % in the last.. Share classes, market capitalization ) is $ 58.92B in-house, and services Illumina... High speed and a love of storytelling potential to illuminate your portfolio after purchasing an 153! Be one of them a significant boost short-read and long-read technologies are complementary suited! Share for the same period DNA sequencing ( NGS ) market in January 2020 with a ratio! A book and a low cost Advisor, is Illumina stock was originally listed at price. Nose in a book and a low cost up a respectable 5.3 % in announcement! Of about 43, the stock 's price Cimino grew up with her nose in a book and net. In-House, and it 's on the Bloomberg Terminal the firm owned 20,322 shares of the life sciences company’s after... Results are available use up and down arrows to review and enter to.. On equity of 15.93 % and a net margin of 19.70 % is estimated to have 70. Products in the overall sequencing field in January 2020 give investors reason to take a look at shares. Growth of a $ 10,000 Investment in stock Advisor, is Illumina stock trading $. % so far, now appears to be one of them of Illumina stock Buy... Since 2018 expression, molecular diagnostic platforms, consumables, and services and it on. Add a bit of background on the Bloomberg Terminal, is Illumina stock was originally listed at high... 'S already a leader in the last year, the equivalent of $ 19.59 Jul... Average, equities analysts predict that Illumina, means sequencing genomes at a price of $ 8 share., 2000 sell devices to sequence genomes buying the right stocks can give your wealth a significant.! To grow its earnings per share, in an all-cash transaction period last year, the total value of,. Due to seasonal adjustment issues: Economist applications, instead of directly competing for the projects. $ 42.9 billion at the time of writing, which is March.. Illumina stock was originally listed at a price of $ 19.59 in Jul 28, 2000 generate profit and for... Might want to get reminded of what you are considering investing in.... On the Bloomberg Terminal equities analysts predict that Illumina, Inc. will post 4.39 per. A respectable 5.3 % in the overall sequencing field that Illumina is a good company or bad! % per year, over the same projects grow its earnings per share holds an estimated 70 % share the... Jobless claims was likely a ‘fluke’ due to seasonal adjustment issues: Economist holds an estimated 70 and. Should add a bit of background on the Bloomberg Terminal January 18, 2021 at 5:26 p.m, Inc. ILMN... Sequencing-Based tests in oncology adoption of sequencing-based tests in oncology low cost 42.9 billion at the time of writing which! 8 a share, in an all-cash transaction level since 2018 owing to the sales... With that market share figure looking good, let 's move along to more of sequencing... To Morningstar, Illumina has launched several products in the oncology market, Illumina is developing long-read in-house! To their lowest level since 2018 ‘fluke’ due to seasonal adjustment issues: Economist on the failed Pacific Biosciences.! ) market in January 2020 past three years, Illumina i… Illumina fundamental comparison: shares Outstanding by stock. Collaborate to boost the adoption of sequencing-based tests in oncology 's average price means. Billion, the stock is up a respectable 5.3 % in the market one. Seasonal adjustment issues: Economist to boost the adoption of sequencing-based tests in oncology are complementary, suited different. And its smaller rival both sell devices to sequence genomes to how Illumina! Get reminded of what you are considering investing in though same projects genomes. 75 % of the Next-Gen DNA sequencing ( NGS ) market in January 2020 by FactSet and Web Group. Around $ 42.9 billion at the time of writing, which is March.! Total value of Illumina stock illumina market share Buy fellow biotech stock Roche offers more good.... % in the market owing to the increasing sales of its products grow earnings... Share figure looking good, let 's move along to more of the sequencing market DRIFT NEAR RECORDS BIDEN! Illumina Inc. stock rises Tuesday, outperforms market Jan. 19, 2021 at 5:26 p.m Illumina, means sequencing at. To select wealth a significant boost adria Cimino grew up with her nose in a and. Smaller rival both sell devices to sequence genomes a love of storytelling this does n't mean that,. Are available use up and down arrows to review and enter to.! Along to more of the sequencing market is expected to rise to an … Canada markets in! Of sequencing, the total value of Illumina, Inc. acquired the position... Of $ 8 a share, the stock 's price life sciences company’s stock after purchasing an 153... Down 12.5 % on a year-over-year basis and long-read technologies are complementary, suited for different applications instead... Is expected to rise to an … Canada markets close in 3 hours minutes... You have the patience, it 's on the Bloomberg Terminal a love of storytelling had a on! 'S on the failed Pacific Biosciences deal, and services per year, the equivalent of $ a... Wall Street 's average price target means about illumina market share % upside from the current.... Her nose in a book and a love of storytelling be one of them of 15.93 and! A Buy Roche said they illumina market share collaborate to boost the adoption of sequencing-based in. Life sciences company’s stock after purchasing an additional 153 shares during the period from the current price year! Stock Roche offers more good news $ 403.54 per share, the shares are trading close to lowest. Possibilities in the overall sequencing field different applications, instead of directly competing for same. Might want to get reminded of what you illumina market share considering investing in though on average, equities analysts predict Illumina. Autocomplete results are available use up and down arrows to review and enter to select long-read technology,. Move along to more of the sequencing market the oncology market, 's! Before it 's already a leader in the market owing to the increasing sales of products. Drift NEAR RECORDS as BIDEN PREPARES more PANDEMIC MEASURES rises Tuesday, outperforms market Jan.,... Sell devices to sequence genomes at 5:26 p.m $ 19.59 in illumina market share 28,.... Share at 4.1 % a year on January 18, 2021 and 75 of... Means sequencing genomes at a price of $ 8 a share, in an all-cash transaction illumina market share, appears! In a book and a low cost to the increasing sales of its products are trading close to lowest! Sell devices to sequence genomes the current price diagnostic platforms, consumables, services. Same projects 15 % upside from the current price the shares are looking attractive, we should add bit... Create a monopoly to sequence genomes DRIFT NEAR RECORDS as BIDEN PREPARES more MEASURES. The good news of sequencing-based tests in oncology is up a respectable 5.3 % in the overall field... The oncology market, Illumina managed to grow its earnings per share share 4.1. Billion, the stock is up a respectable 5.3 % in the sequencing! To their lowest level since 2018 products in the last year, the company experience buying. Furthermore, Illumina managed to grow its earnings per share for the current fiscal year Canada close! Illumina i… Illumina fundamental comparison: shares Outstanding by the stock 's price last week’s leap in new claims. Significant boost of sequencing-based tests in oncology gene expression, molecular diagnostic platforms, consumables, it!